{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:48:55Z","timestamp":1791668935390,"version":"4.3.4"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"jon and nancy wilkins fund for als research"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Amyotrophic Lateral Sclerosis (ALS) is a devastating neurodegenerative disease in which many processes are detected including (neuro)inflammation. Many drugs have been tested for ALS in clinical trials but most have failed to reach their primary endpoints. The development and inclusion of different types of biomarkers in diagnosis and clinical trials can assist in determining target engagement of a drug, in distinguishing between ALS and other diseases, and in predicting disease progression rate, drug responsiveness, or an adverse event. Ideally, among other characteristics, a biomarker in ALS correlates highly with a disease process in the central nervous system or with disease progression and is conveniently obtained in a peripheral tissue. Here, we describe the state of biomarkers of inflammation in ALS by focusing on peripherally detectable and cellular responses from blood cells, and provide new (combinatorial) directions for exploration that are now feasible due to technological advancements.<\/jats:p>","DOI":"10.1186\/s13024-022-00515-1","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T11:03:27Z","timestamp":1643022207000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis"],"prefix":"10.1186","volume":"17","author":[{"given":"Kim A.","family":"Staats","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Borchelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mal\u00fa G\u00e1mez","family":"Tansey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0809-2977","authenticated-orcid":false,"given":"James","family":"Wymer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,24]]},"reference":[{"issue":"11","key":"515_CR1","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S1474-4422(14)70129-2","volume":"13","author":"H Mitsumoto","year":"2014","unstructured":"Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol. 2014;13(11):1127\u201338. https:\/\/doi.org\/10.1016\/S1474-4422(14)70129-2.","journal-title":"Lancet Neurol"},{"key":"515_CR2","unstructured":"FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]. Silver Spring (MD): Food and Drug Administration (US); 2016 [cited 2020]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK326791\/"},{"issue":"12","key":"515_CR3","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/S1474-4422(07)70270-3","volume":"6","author":"PH Gordon","year":"2007","unstructured":"Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 2007;6(12):1045\u201353. https:\/\/doi.org\/10.1016\/S1474-4422(07)70270-3.","journal-title":"Lancet Neurol"},{"issue":"2","key":"515_CR4","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3988\/jcn.2015.11.2.164","volume":"11","author":"N Amirzagar","year":"2015","unstructured":"Amirzagar N, Nafissi S, Tafakhori A, Modabbernia A, Amirzargar A, Ghaffarpour M, et al. Granulocyte Colony-stimulating factor for amyotrophic lateral sclerosis: a randomized, double-blind. Placebo-Controlled Study of Iranian Patients J Clin Neurol. 2015;11(2):164. https:\/\/doi.org\/10.3988\/jcn.2015.11.2.164.","journal-title":"Placebo-Controlled Study of Iranian Patients J Clin Neurol"},{"issue":"11","key":"515_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-029449","volume":"9","author":"B Urbi","year":"2019","unstructured":"Urbi B, Broadley S, Bedlack R, Russo E, Sabet A. Study protocol for a randomised, double-blind, placebo-controlled study evaluating the efficacy of cannabis-based medicine extract in slowing the disease pRogression of amyotrophic lateral sclerosis or motor neurone disease: the EMERALD trial. BMJ Open. 2019;9(11):e029449. https:\/\/doi.org\/10.1136\/bmjopen-2019-029449.","journal-title":"BMJ Open"},{"issue":"1-2","key":"515_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/21678421.2019.1632346","volume":"21","author":"JS Mora","year":"2020","unstructured":"Mora JS, Genge A, Chio A, Estol CJ, Chaverri D, Hern\u00e1ndez M, et al. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph Lateral Scler Front Degener. 2020;21(1-2):5\u201314. https:\/\/doi.org\/10.1080\/21678421.2019.1632346.","journal-title":"Amyotroph Lateral Scler Front Degener"},{"issue":"2","key":"515_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.neuron.2011.09.010","volume":"72","author":"AE Renton","year":"2011","unstructured":"Renton AE, Majounie E, Waite A, Sim\u00f3n-S\u00e1nchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2):257\u201368. https:\/\/doi.org\/10.1016\/j.neuron.2011.09.010.","journal-title":"Neuron."},{"issue":"2","key":"515_CR8","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.neuron.2011.09.011","volume":"72","author":"M DeJesus-Hernandez","year":"2011","unstructured":"DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2):245\u201356. https:\/\/doi.org\/10.1016\/j.neuron.2011.09.011.","journal-title":"Neuron."},{"issue":"1","key":"515_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/nn.3584","volume":"17","author":"AE Renton","year":"2014","unstructured":"Renton AE, Chi\u00f2 A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014;17(1):17\u201323. https:\/\/doi.org\/10.1038\/nn.3584.","journal-title":"Nat Neurosci"},{"issue":"9","key":"515_CR10","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJM199403033300901","volume":"330","author":"G Bensimon","year":"1994","unstructured":"Bensimon G, Lacomblez L, Meininger V. A controlled trial of Riluzole in amyotrophic lateral sclerosis. N Engl J Med. 1994;330(9):585\u201391. https:\/\/doi.org\/10.1056\/NEJM199403033300901.","journal-title":"N Engl J Med"},{"issue":"1","key":"515_CR11","doi-asserted-by":"publisher","first-page":"12408","DOI":"10.1038\/ncomms12408","volume":"7","author":"KC Arthur","year":"2016","unstructured":"Arthur KC, Calvo A, Price TR, Geiger JT, Chi\u00f2 A, Traynor BJ. Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nat Commun. 2016;7(1):12408. https:\/\/doi.org\/10.1038\/ncomms12408.","journal-title":"Nat Commun"},{"issue":"2","key":"515_CR12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/14728214.2020.1769067","volume":"25","author":"A Barp","year":"2020","unstructured":"Barp A, Gerardi F, Lizio A, Sansone VA, Lunetta C. Emerging drugs for the treatment of amyotrophic lateral sclerosis: a focus on recent phase 2 trials. Expert Opin Emerg Drugs. 2020;25(2):145\u201364. https:\/\/doi.org\/10.1080\/14728214.2020.1769067.","journal-title":"Expert Opin Emerg Drugs"},{"issue":"11","key":"515_CR13","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1474-4422(16)30199-5","volume":"15","author":"A Al-Chalabi","year":"2016","unstructured":"Al-Chalabi A, Hardiman O, Kiernan MC, Chi\u00f2 A, Rix-Brooks B, van den Berg LH. Amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurol. 2016;15(11):1182\u201394. https:\/\/doi.org\/10.1016\/S1474-4422(16)30199-5.","journal-title":"Lancet Neurol"},{"issue":"1","key":"515_CR14","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/S1474-4422(08)70293-X","volume":"8","author":"MR Turner","year":"2009","unstructured":"Turner MR, Kiernan MC, Leigh PN, Talbot K. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol. 2009;8(1):94\u2013109. https:\/\/doi.org\/10.1016\/S1474-4422(08)70293-X.","journal-title":"Lancet Neurol"},{"issue":"12","key":"515_CR15","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1212\/WNL.0000000000003741","volume":"88","author":"SR Shepheard","year":"2017","unstructured":"Shepheard SR, Wuu J, Cardoso M, Wiklendt L, Dinning PG, Chataway T, et al. Urinary p75ECD: a prognostic, disease progression, and pharmacodynamic biomarker in ALS. Neurology. 2017;88(12):1137\u201343. https:\/\/doi.org\/10.1212\/WNL.0000000000003741.","journal-title":"Neurology."},{"issue":"3","key":"515_CR16","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s00415-017-8730-6","volume":"265","author":"D Rossi","year":"2018","unstructured":"Rossi D, Volanti P, Brambilla L, Colletti T, Spataro R, La Bella V. CSF neurofilament proteins as diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis. J Neurol. 2018;265(3):510\u201321. https:\/\/doi.org\/10.1007\/s00415-017-8730-6.","journal-title":"J Neurol"},{"issue":"2","key":"515_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/jnnp-2018-318704","volume":"90","author":"F Verde","year":"2019","unstructured":"Verde F, Steinacker P, Weishaupt JH, Kassubek J, Oeckl P, Halbgebauer S, et al. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2019;90(2):157\u201364. https:\/\/doi.org\/10.1136\/jnnp-2018-318704.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"515_CR18","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3389\/fneur.2020.00279","volume":"11","author":"PA McCombe","year":"2020","unstructured":"McCombe PA, Lee JD, Woodruff TM, Henderson RD. The peripheral immune system and amyotrophic lateral sclerosis. Front Neurol. 2020;11:279. https:\/\/doi.org\/10.3389\/fneur.2020.00279.","journal-title":"Front Neurol"},{"issue":"3","key":"515_CR19","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S1474-4422(11)70015-1","volume":"10","author":"T Philips","year":"2011","unstructured":"Philips T, Robberecht W. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol. 2011;10(3):253\u201363. https:\/\/doi.org\/10.1016\/S1474-4422(11)70015-1.","journal-title":"Lancet Neurol"},{"issue":"2","key":"515_CR20","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S1474-4422(18)30394-6","volume":"18","author":"DR Beers","year":"2019","unstructured":"Beers DR, Appel SH. Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies. Lancet Neurol. 2019;18(2):211\u201320. https:\/\/doi.org\/10.1016\/S1474-4422(18)30394-6.","journal-title":"Lancet Neurol"},{"issue":"5-6","key":"515_CR21","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3109\/21678421.2014.903974","volume":"15","author":"S Paganoni","year":"2014","unstructured":"Paganoni S, Macklin EA, Lee A, Murphy A, Chang J, Zipf A, et al. Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS). Amyotroph Lateral Scler Front Degener. 2014;15(5-6):453\u20136. https:\/\/doi.org\/10.3109\/21678421.2014.903974.","journal-title":"Amyotroph Lateral Scler Front Degener"},{"issue":"1","key":"515_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40364-019-0154-2","volume":"7","author":"A Khoo","year":"2019","unstructured":"Khoo A, Frasca J, Schultz D. Measuring disease activity and predicting response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Biomark Res. 2019;7(1):3. https:\/\/doi.org\/10.1186\/s40364-019-0154-2.","journal-title":"Biomark Res"},{"issue":"2","key":"515_CR23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.27046","volume":"63","author":"AM Stino","year":"2021","unstructured":"Stino AM, Naddaf E, Dyck PJ, Dyck PJB. Chronic inflammatory demyelinating polyradiculoneuropathy\u2014diagnostic pitfalls and treatment approach. Muscle Nerve. 2021;63(2):157\u201369. https:\/\/doi.org\/10.1002\/mus.27046.","journal-title":"Muscle Nerve"},{"key":"515_CR24","doi-asserted-by":"publisher","first-page":"574133","DOI":"10.3389\/fmolb.2020.574133","volume":"7","author":"L Porter","year":"2020","unstructured":"Porter L, Shoushtarizadeh A, Jelinek GA, Brown CR, Lim CK, de Livera AM, et al. Metabolomic biomarkers of multiple sclerosis: a systematic review. Front Mol Biosci. 2020;7:574133. https:\/\/doi.org\/10.3389\/fmolb.2020.574133.","journal-title":"Front Mol Biosci"},{"key":"515_CR25","doi-asserted-by":"publisher","first-page":"146625","DOI":"10.1016\/j.brainres.2019.146625","volume":"2020","author":"AM Rossor","year":"1729","unstructured":"Rossor AM, Shy ME, Reilly MM. Are we prepared for clinical trials in Charcot-Marie-tooth disease? Brain Res. 1729;2020:146625. https:\/\/doi.org\/10.1016\/j.brainres.2019.146625.","journal-title":"Brain Res"},{"issue":"1","key":"515_CR26","doi-asserted-by":"publisher","first-page":"15295","DOI":"10.1038\/s41598-020-72247-5","volume":"10","author":"DR Beers","year":"2020","unstructured":"Beers DR, Zhao W, Neal DW, Thonhoff JR, Thome AD, Faridar A, et al. Elevated acute phase proteins reflect peripheral inflammation and disease severity in patients with amyotrophic lateral sclerosis. Sci Rep. 2020;10(1):15295. https:\/\/doi.org\/10.1038\/s41598-020-72247-5.","journal-title":"Sci Rep"},{"issue":"1","key":"515_CR27","doi-asserted-by":"publisher","first-page":"5941","DOI":"10.1038\/s41598-020-62756-8","volume":"10","author":"M Jin","year":"2020","unstructured":"Jin M, G\u00fcnther R, Akg\u00fcn K, Hermann A, Ziemssen T. Peripheral proinflammatory Th1\/Th17 immune cell shift is linked to disease severity in amyotrophic lateral sclerosis. Sci Rep. 2020;10(1):5941. https:\/\/doi.org\/10.1038\/s41598-020-62756-8.","journal-title":"Sci Rep"},{"issue":"6","key":"515_CR28","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1600-0404.2008.01112.x","volume":"119","author":"D Keizman","year":"2009","unstructured":"Keizman D, Rogowski O, Berliner S, Ish-Shalom M, Maimon N, Nefussy B, et al. Low-grade systemic inflammation in patients with amyotrophic lateral sclerosis. Acta Neurol Scand. 2009;119(6):383\u20139. https:\/\/doi.org\/10.1111\/j.1600-0404.2008.01112.x.","journal-title":"Acta Neurol Scand"},{"key":"515_CR29","doi-asserted-by":"publisher","first-page":"552295","DOI":"10.3389\/fneur.2020.552295","volume":"11","author":"R Tortelli","year":"2020","unstructured":"Tortelli R, Zecca C, Piccininni M, Benmahamed S, Dell\u2019Abate MT, Barulli MR, et al. Plasma inflammatory cytokines are elevated in ALS. Front Neurol. 2020;11:552295. https:\/\/doi.org\/10.3389\/fneur.2020.552295.","journal-title":"Front Neurol"},{"issue":"7-8","key":"515_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21678421.2020.1779303","volume":"21","author":"L Mohanty","year":"2020","unstructured":"Mohanty L, Henderson RD, McCombe PA, Lee A. Levels of clusterin, CD5L, ficolin-3, and gelsolin in ALS patients and controls. Amyotroph Lateral Scler Front Degener. 2020;21(7-8):1\u20134. https:\/\/doi.org\/10.1080\/21678421.2020.1779303.","journal-title":"Amyotroph Lateral Scler Front Degener"},{"issue":"8","key":"515_CR31","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1089\/brain.2020.0741","volume":"10","author":"A Polverino","year":"2020","unstructured":"Polverino A, Rucco R, Stillitano I, Bonavita S, Grimaldi M, Minino R, et al. In amyotrophic lateral sclerosis blood cytokines are altered, but do not correlate with changes in brain topology. Brain Connect. 2020;10(8):411\u201321. https:\/\/doi.org\/10.1089\/brain.2020.0741.","journal-title":"Brain Connect"},{"issue":"7","key":"515_CR32","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/acn3.51078","volume":"7","author":"F Huang","year":"2020","unstructured":"Huang F, Zhu Y, Hsiao-Nakamoto J, Tang X, Dugas JC, Moscovitch-Lopatin M, et al. Longitudinal biomarkers in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2020;7(7):1103\u201316. https:\/\/doi.org\/10.1002\/acn3.51078.","journal-title":"Ann Clin Transl Neurol"},{"key":"515_CR33","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jns.2019.01.026","volume":"398","author":"A Pronto-Laborinho","year":"2019","unstructured":"Pronto-Laborinho A, Pinto S, Gromicho M, Pereira M, Swash M, de Carvalho M. Interleukin-6 and amyotrophic lateral sclerosis. J Neurol Sci. 2019;398:50\u20133. https:\/\/doi.org\/10.1016\/j.jns.2019.01.026.","journal-title":"J Neurol Sci"},{"key":"515_CR34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jns.2018.08.033","volume":"394","author":"L de Prado","year":"2018","unstructured":"de Prado L. GR, Rocha NP, de Souza LC, Bicalho ICS, Gomez RS, Vidigal-Lopes M, et al. Longitudinal assessment of clinical and inflammatory markers in patients with amyotrophic lateral sclerosis J Neurol Sci. 2018;394:69\u201374. https:\/\/doi.org\/10.1016\/j.jns.2018.08.033.","journal-title":"Longitudinal assessment of clinical and inflammatory markers in patients with amyotrophic lateral sclerosis J Neurol Sci"},{"key":"515_CR35","doi-asserted-by":"publisher","first-page":"546","DOI":"10.3389\/fneur.2017.00546","volume":"8","author":"P Andr\u00e9s-Benito","year":"2017","unstructured":"Andr\u00e9s-Benito P, Moreno J, Dom\u00ednguez R, Aso E, Povedano M, Ferrer I. Inflammatory gene expression in whole peripheral blood at early stages of sporadic amyotrophic lateral sclerosis. Front Neurol. 2017;8:546. https:\/\/doi.org\/10.3389\/fneur.2017.00546.","journal-title":"Front Neurol"},{"issue":"1","key":"515_CR36","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13195-017-0316-0","volume":"9","author":"KS Sheinerman","year":"2017","unstructured":"Sheinerman KS, Toledo JB, Tsivinsky VG, Irwin D, Grossman M, Weintraub D, et al. Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases. Alzheimers Res Ther. 2017;9(1):89. https:\/\/doi.org\/10.1186\/s13195-017-0316-0.","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"515_CR37","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/ane.12851","volume":"137","author":"AC Pronto-Laborinho","year":"2018","unstructured":"Pronto-Laborinho AC. Gromicho M, Pereira M, Pinto S, Barros M do a, Swash M, et al. plasma level of club-cell (CC-16) predicts outcome in amyotrophic lateral sclerosis. Acta Neurol Scand. 2018;137(2):233\u20137. https:\/\/doi.org\/10.1111\/ane.12851.","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"515_CR38","doi-asserted-by":"publisher","first-page":"9094","DOI":"10.1038\/s41598-017-09097-1","volume":"7","author":"Y Hu","year":"2017","unstructured":"Hu Y, Cao C, Qin X-Y, Yu Y, Yuan J, Zhao Y, et al. Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: a meta-analysis study. Sci Rep. 2017;7(1):9094. https:\/\/doi.org\/10.1038\/s41598-017-09097-1.","journal-title":"Sci Rep"},{"issue":"1","key":"515_CR39","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1017\/cjn.2016.284","volume":"44","author":"H Blasco","year":"2017","unstructured":"Blasco H, Garcon G, Patin F, Veyrat-Durebex C, Boyer J, Devos D, et al. Panel of oxidative stress and inflammatory biomarkers in ALS: a pilot study. Can J Neurol Sci J Can Sci Neurol. 2017;44(1):90\u20135. https:\/\/doi.org\/10.1017\/cjn.2016.284.","journal-title":"Can J Neurol Sci J Can Sci Neurol"},{"issue":"1","key":"515_CR40","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/1742-2094-11-94","volume":"11","author":"P Italiani","year":"2014","unstructured":"Italiani P, Carlesi C, Giungato P, Puxeddu I, Borroni B, Boss\u00f9 P, et al. Evaluating the levels of interleukin-1 family cytokines in sporadic amyotrophic lateral sclerosis. J Neuroinflammation. 2014;11(1):94. https:\/\/doi.org\/10.1186\/1742-2094-11-94.","journal-title":"J Neuroinflammation"},{"issue":"1-2","key":"515_CR41","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jneuroim.2012.05.001","volume":"249","author":"CY Lin","year":"2012","unstructured":"Lin CY, Pfluger CM, Henderson RD, McCombe PA. Reduced levels of interleukin 33 and increased levels of soluble ST2 in subjects with amyotrophic lateral sclerosis. J Neuroimmunol. 2012;249(1-2):93\u20135. https:\/\/doi.org\/10.1016\/j.jneuroim.2012.05.001.","journal-title":"J Neuroimmunol"},{"issue":"1","key":"515_CR42","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/1742-2094-7-76","volume":"7","author":"M Fiala","year":"2010","unstructured":"Fiala M, Chattopadhay M, La Cava A, Tse E, Liu G, Lourenco E, et al. IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patients. J Neuroinflammation. 2010;7(1):76. https:\/\/doi.org\/10.1186\/1742-2094-7-76.","journal-title":"J Neuroinflammation"},{"issue":"2","key":"515_CR43","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s12640-009-9129-7","volume":"18","author":"Y Chen","year":"2010","unstructured":"Chen Y, Stankovic R, Cullen KM, Meininger V, Garner B, Coggan S, et al. The kynurenine pathway and inflammation in amyotrophic lateral sclerosis. Neurotox Res. 2010;18(2):132\u201342. https:\/\/doi.org\/10.1007\/s12640-009-9129-7.","journal-title":"Neurotox Res"},{"issue":"6","key":"515_CR44","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/j.1468-1331.2009.02560.x","volume":"16","author":"J Kuhle","year":"2009","unstructured":"Kuhle J, Lindberg RLP, Regeniter A, Mehling M, Steck AJ, Kappos L, et al. Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis. Eur J Neurol. 2009;16(6):771\u20134. https:\/\/doi.org\/10.1111\/j.1468-1331.2009.02560.x.","journal-title":"Eur J Neurol"},{"issue":"6","key":"515_CR45","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s11064-007-9564-x","volume":"33","author":"GN Babu","year":"2008","unstructured":"Babu GN, Kumar A, Chandra R, Puri SK, Kalita J, Misra UK. Elevated inflammatory markers in a Group of Amyotrophic Lateral Sclerosis Patients from northern India. Neurochem Res. 2008;33(6):1145\u20139. https:\/\/doi.org\/10.1007\/s11064-007-9564-x.","journal-title":"Neurochem Res"},{"issue":"5","key":"515_CR46","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/17482960701419232","volume":"8","author":"M Rentzos","year":"2007","unstructured":"Rentzos M, Nikolaou C, Rombos A, Boufidou F, Zoga M, Dimitrakopoulos A, et al. RANTES levels are elevated in serum and cerebrospinal fluid in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2007;8(5):283\u20137. https:\/\/doi.org\/10.1080\/17482960701419232.","journal-title":"Amyotroph Lateral Scler"},{"issue":"4","key":"515_CR47","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/mus.20376","volume":"32","author":"P Baron","year":"2005","unstructured":"Baron P, Bussini S, Cardin V, Corbo M, Conti G, Galimberti D, et al. Production of monocyte chemoattractant protein-1 in amyotrophic lateral sclerosis. Muscle Nerve. 2005;32(4):541\u20134. https:\/\/doi.org\/10.1002\/mus.20376.","journal-title":"Muscle Nerve"},{"issue":"1-2","key":"515_CR48","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jneuroim.2003.08.042","volume":"144","author":"H Wilms","year":"2003","unstructured":"Wilms H. Intrathecal synthesis of monocyte chemoattractant protein-1 (MCP-1) in amyotrophic lateral sclerosis: further evidence for microglial activation in neurodegeneration. J Neuroimmunol. 2003;144(1-2):139\u201342. https:\/\/doi.org\/10.1016\/j.jneuroim.2003.08.042.","journal-title":"J Neuroimmunol"},{"issue":"4","key":"515_CR49","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.celrep.2012.02.009","volume":"1","author":"M Etzrodt","year":"2012","unstructured":"Etzrodt M, Cortez-Retamozo V, Newton A, Zhao J, Ng A, Wildgruber M, et al. Regulation of monocyte functional heterogeneity by miR-146a and Relb. Cell Rep. 2012;1(4):317\u201324. https:\/\/doi.org\/10.1016\/j.celrep.2012.02.009.","journal-title":"Cell Rep"},{"issue":"6","key":"515_CR50","doi-asserted-by":"publisher","first-page":"200116","DOI":"10.1098\/rsob.200116","volume":"10","author":"SA Banack","year":"2020","unstructured":"Banack SA, Dunlop RA, Cox PA. An miRNA fingerprint using neural-enriched extracellular vesicles from blood plasma: towards a biomarker for amyotrophic lateral sclerosis\/motor neuron disease. Open Biol. 2020;10(6):200116. https:\/\/doi.org\/10.1098\/rsob.200116.","journal-title":"Open Biol"},{"issue":"5-6","key":"515_CR51","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1080\/21678421.2018.1433689","volume":"19","author":"Z Xu","year":"2018","unstructured":"Xu Z, Lee A, Nouwens A, Henderson RD, McCombe PA. Mass spectrometry analysis of plasma from amyotrophic lateral sclerosis and control subjects. Amyotroph Lateral Scler Front Degener. 2018;19(5-6):362\u201376. https:\/\/doi.org\/10.1080\/21678421.2018.1433689.","journal-title":"Amyotroph Lateral Scler Front Degener"},{"issue":"7823","key":"515_CR52","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41586-020-2625-x","volume":"585","author":"ME McCauley","year":"2020","unstructured":"McCauley ME, O\u2019Rourke JG, Y\u00e1\u00f1ez A, Markman JL, Ho R, Wang X, et al. C9orf72 in myeloid cells suppresses STING-induced inflammation. Nature. 2020;585(7823):96\u2013101. https:\/\/doi.org\/10.1038\/s41586-020-2625-x.","journal-title":"Nature."},{"issue":"1","key":"515_CR53","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12974-018-1135-3","volume":"15","author":"C Perner","year":"2018","unstructured":"Perner C, Perner F, Stubendorff B, F\u00f6rster M, Witte OW, Heidel FH, et al. Dysregulation of chemokine receptor expression and function in leukocytes from ALS patients. J Neuroinflammation. 2018;15(1):99. https:\/\/doi.org\/10.1186\/s12974-018-1135-3.","journal-title":"J Neuroinflammation"},{"issue":"1","key":"515_CR54","doi-asserted-by":"publisher","first-page":"7853","DOI":"10.1038\/s41598-017-08233-1","volume":"7","author":"M Rusconi","year":"2017","unstructured":"Rusconi M, Gerardi F, Santus W, Lizio A, Sansone VA, Lunetta C, et al. Inflammatory role of dendritic cells in amyotrophic lateral sclerosis revealed by an analysis of patients\u2019 peripheral blood. Sci Rep. 2017;7(1):7853. https:\/\/doi.org\/10.1038\/s41598-017-08233-1.","journal-title":"Sci Rep"},{"key":"515_CR55","doi-asserted-by":"publisher","first-page":"e0182002","DOI":"10.1371\/journal.pone.0182002","volume":"12","author":"MP Gustafson","year":"2017","unstructured":"Gustafson MP, Staff NP, Bornschlegl S, Butler GW, Maas ML, Kazamel M, et al. Comprehensive immune profiling reveals substantial immune system alterations in a subset of patients with amyotrophic lateral sclerosis. Raoul C, editor. PLOS ONE. 2017;12:e0182002.","journal-title":"PLOS ONE"},{"issue":"6","key":"515_CR56","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1001\/jamaneurol.2017.0357","volume":"74","author":"W Zhao","year":"2017","unstructured":"Zhao W, Beers DR, Hooten KG, Sieglaff DH, Zhang A, Kalyana-Sundaram S, et al. Characterization of gene expression phenotype in amyotrophic lateral sclerosis monocytes. JAMA Neurol. 2017;74(6):677\u201385. https:\/\/doi.org\/10.1001\/jamaneurol.2017.0357.","journal-title":"JAMA Neurol"},{"issue":"10","key":"515_CR57","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1096\/fj.201600259RR","volume":"30","author":"L Lam","year":"2016","unstructured":"Lam L, Chin L, Halder RC, Sagong B, Famenini S, Sayre J, et al. Epigenetic changes in T-cell and monocyte signatures and production of neurotoxic cytokines in ALS patients. FASEB J Off Publ Fed Am Soc Exp Biol. 2016;30(10):3461\u201373. https:\/\/doi.org\/10.1096\/fj.201600259RR.","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol"},{"issue":"1","key":"515_CR58","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.clim.2013.04.010","volume":"148","author":"M Saresella","year":"2013","unstructured":"Saresella M, Piancone F, Tortorella P, Marventano I, Gatti A, Caputo D, et al. T helper-17 activation dominates the immunologic milieu of both amyotrophic lateral sclerosis and progressive multiple sclerosis. Clin Immunol. 2013;148(1):79\u201388. https:\/\/doi.org\/10.1016\/j.clim.2013.04.010.","journal-title":"Clin Immunol"},{"issue":"2","key":"515_CR59","first-page":"129","volume":"2","author":"M Fiala","year":"2013","unstructured":"Fiala M, Mizwicki MT, Weitzman R, Magpantay L, Nishimoto N. Tocilizumab infusion therapy normalizes inflammation in sporadic ALS patients. Am J Neurodegener Dis. 2013;2(2):129\u201339.","journal-title":"Am J Neurodegener Dis"},{"issue":"3","key":"515_CR60","first-page":"305","volume":"1","author":"MT Mizwicki","year":"2012","unstructured":"Mizwicki MT, Fiala M, Magpantay L, Aziz N, Sayre J, Liu G, et al. Tocilizumab attenuates inflammation in ALS patients through inhibition of IL6 receptor signaling. Am J Neurodegener Dis. 2012;1(3):305\u201315.","journal-title":"Am J Neurodegener Dis"},{"issue":"1-2","key":"515_CR61","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jneuroim.2004.10.009","volume":"159","author":"R Zhang","year":"2005","unstructured":"Zhang R, Gascon R, Miller RG, Gelinas DF, Mass J, Hadlock K, et al. Evidence for systemic immune system alterations in sporadic amyotrophic lateral sclerosis (sALS). J Neuroimmunol. 2005;159(1-2):215\u201324. https:\/\/doi.org\/10.1016\/j.jneuroim.2004.10.009.","journal-title":"J Neuroimmunol"},{"issue":"6","key":"515_CR62","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/ane.13401","volume":"143","author":"A Olsson","year":"2021","unstructured":"Olsson A, Gustavsen S, Gissel\u00f8 Lauridsen K, Chenoufi Hasselbalch I, Sellebjerg F, Bach S\u00f8ndergaard H, et al. Neutrophil-to-lymphocyte ratio and CRP as biomarkers in multiple sclerosis: a systematic review. Acta Neurol Scand. 2021;143(6):577\u201386. https:\/\/doi.org\/10.1111\/ane.13401.","journal-title":"Acta Neurol Scand"},{"key":"515_CR63","doi-asserted-by":"publisher","first-page":"602235","DOI":"10.3389\/fnins.2020.602235","volume":"14","author":"S Gururaj","year":"2020","unstructured":"Gururaj S, Sampognaro PJ, Argouarch AR, Kao AW. Progranulin adsorbs to polypropylene tubes and disrupts functional assays: implications for research, biomarker studies, and therapeutics. Front Neurosci. 2020;14:602235. https:\/\/doi.org\/10.3389\/fnins.2020.602235.","journal-title":"Front Neurosci"},{"issue":"2","key":"515_CR64","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/mus.24979","volume":"53","author":"M Benatar","year":"2016","unstructured":"Benatar M, Boylan K, Jeromin A, Rutkove SB, Berry J, Atassi N, et al. ALS biomarkers for therapy development: state of the field and future directions. Muscle Nerve. 2016;53(2):169\u201382. https:\/\/doi.org\/10.1002\/mus.24979.","journal-title":"Muscle Nerve"},{"key":"515_CR65","doi-asserted-by":"publisher","first-page":"629332","DOI":"10.3389\/fneur.2021.629332","volume":"12","author":"N Gaur","year":"2021","unstructured":"Gaur N, Huss E, Prell T, Steinbach R, Guerra J, Srivastava A, et al. Monocyte-derived macrophages contribute to Chitinase dysregulation in amyotrophic lateral sclerosis: a pilot study. Front Neurol. 2021;12:629332. https:\/\/doi.org\/10.3389\/fneur.2021.629332.","journal-title":"Front Neurol"},{"key":"515_CR66","unstructured":". F. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/amyotrophic-lateral-sclerosis-developing-drugs-treatment-guidance-industry."},{"issue":"11","key":"515_CR67","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1111\/ene.14409","volume":"27","author":"J Sun","year":"2020","unstructured":"Sun J, Carrero JJ, Zagai U, Evans M, Ingre C, Pawitan Y, et al. Blood biomarkers and prognosis of amyotrophic lateral sclerosis. Eur J Neurol. 2020;27(11):2125\u201333. https:\/\/doi.org\/10.1111\/ene.14409.","journal-title":"Eur J Neurol"},{"key":"515_CR68","unstructured":"Bendotti C, Bonetto V, Pupillo E, Logroscino G, Al-Chalabi A, Lunetta C, et al. Focus on the heterogeneity of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Front Degener. 2020:1\u201311."},{"issue":"6","key":"515_CR69","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1001\/jamaneurol.2016.6179","volume":"74","author":"C Lunetta","year":"2017","unstructured":"Lunetta C, Lizio A, Maestri E, Sansone VA, Mora G, Miller RG, et al. Serum C-reactive protein as a prognostic biomarker in amyotrophic lateral sclerosis. JAMA Neurol. 2017;74(6):660\u20137. https:\/\/doi.org\/10.1001\/jamaneurol.2016.6179.","journal-title":"JAMA Neurol"},{"issue":"1","key":"515_CR70","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1038\/s41598-019-39739-5","volume":"9","author":"D Devos","year":"2019","unstructured":"Devos D, Moreau C, Kyheng M, Gar\u00e7on G, Rolland AS, Blasco H, et al. A ferroptosis\u2013based panel of prognostic biomarkers for amyotrophic lateral sclerosis. Sci Rep. 2019;9(1):2918. https:\/\/doi.org\/10.1038\/s41598-019-39739-5.","journal-title":"Sci Rep"},{"issue":"1","key":"515_CR71","first-page":"60","volume":"1","author":"G Liu","year":"2012","unstructured":"Liu G, Fiala M, Mizwicki MT, Sayre J, Magpantay L, Siani A, et al. Neuronal phagocytosis by inflammatory macrophages in ALS spinal cord: inhibition of inflammation by resolvin D1. Am J Neurodegener Dis. 2012;1(1):60\u201374.","journal-title":"Am J Neurodegener Dis"},{"issue":"7-8","key":"515_CR72","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3109\/21678421.2014.951940","volume":"15","author":"RG Miller","year":"2014","unstructured":"Miller RG, Zhang R, Block G, Katz J, Barohn R, Kasarskis E, et al. NP001 regulation of macrophage activation markers in ALS: a phase I clinical and biomarker study. Amyotroph Lateral Scler Front Degener. 2014;15(7-8):601\u20139. https:\/\/doi.org\/10.3109\/21678421.2014.951940.","journal-title":"Amyotroph Lateral Scler Front Degener"},{"issue":"1","key":"515_CR73","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/emmm.201201544","volume":"5","author":"JS Henkel","year":"2013","unstructured":"Henkel JS, Beers DR, Wen S, Rivera AL, Toennis KM, Appel JE, et al. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med. 2013;5(1):64\u201379. https:\/\/doi.org\/10.1002\/emmm.201201544.","journal-title":"EMBO Mol Med"},{"issue":"Pt 3","key":"515_CR74","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1093\/brain\/118.3.707","volume":"118","author":"LJ Haverkamp","year":"1995","unstructured":"Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain J Neurol. 1995;118(Pt 3):707\u201319. https:\/\/doi.org\/10.1093\/brain\/118.3.707.","journal-title":"Brain J Neurol"},{"issue":"5","key":"515_CR75","doi-asserted-by":"publisher","first-page":"e451","DOI":"10.1212\/WNL.0000000000006855","volume":"92","author":"RPA van Eijk","year":"2019","unstructured":"van Eijk RPA, Westeneng H-J, Nikolakopoulos S, Verhagen IE, van Es MA, Eijkemans MJC, et al. Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials. Neurology. 2019;92(5):e451\u201360. https:\/\/doi.org\/10.1212\/WNL.0000000000006855.","journal-title":"Neurology."},{"issue":"5","key":"515_CR76","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S1474-4422(18)30089-9","volume":"17","author":"H-J Westeneng","year":"2018","unstructured":"Westeneng H-J, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17(5):423\u201333. https:\/\/doi.org\/10.1016\/S1474-4422(18)30089-9.","journal-title":"Lancet Neurol"},{"issue":"5-6","key":"515_CR77","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1080\/21678421.2019.1587634","volume":"20","author":"M Benatar","year":"2019","unstructured":"Benatar M, Turner MR, Wuu J. Defining pre-symptomatic amyotrophic lateral sclerosis. Amyotroph Lateral Scler Front Degener. 2019;20(5-6):303\u20139. https:\/\/doi.org\/10.1080\/21678421.2019.1587634.","journal-title":"Amyotroph Lateral Scler Front Degener"},{"issue":"35","key":"515_CR78","doi-asserted-by":"publisher","first-page":"21813","DOI":"10.1073\/pnas.2001429117","volume":"117","author":"M Wainberg","year":"2020","unstructured":"Wainberg M, Magis AT, Earls JC, Lovejoy JC, Sinnott-Armstrong N, Omenn GS, et al. Multiomic blood correlates of genetic risk identify presymptomatic disease alterations. Proc Natl Acad Sci. 2020;117(35):21813\u201320. https:\/\/doi.org\/10.1073\/pnas.2001429117.","journal-title":"Proc Natl Acad Sci"},{"key":"515_CR79","doi-asserted-by":"crossref","unstructured":"Wang H, Shen X, Li J, Suckling J, Tan C, Wang Y, et al. Clinical and biomarker trajectories in sporadic Alzheimer\u2019s disease: A longitudinal study. Alzheimers Dement Diagn Assess Dis Monit. 2020;12 Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/dad2.12095. Cited 2021 Feb 20.","DOI":"10.1002\/dad2.12095"},{"issue":"1","key":"515_CR80","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/ana.25276","volume":"84","author":"M Benatar","year":"2018","unstructured":"Benatar M, Wuu J, Andersen PM, Lombardi V, Malaspina A. Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol. 2018;84(1):130\u20139. https:\/\/doi.org\/10.1002\/ana.25276.","journal-title":"Ann Neurol"},{"issue":"14","key":"515_CR81","doi-asserted-by":"publisher","first-page":"e1610","DOI":"10.1212\/WNL.0000000000007242","volume":"92","author":"LH van den Berg","year":"2019","unstructured":"van den Berg LH, Sorenson E, Gronseth G, Macklin EA, Andrews J, Baloh RH, et al. Revised Airlie house consensus guidelines for design and implementation of ALS clinical trials. Neurology. 2019;92(14):e1610\u201323. https:\/\/doi.org\/10.1212\/WNL.0000000000007242.","journal-title":"Neurology."},{"issue":"2","key":"515_CR82","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41582-020-00434-z","volume":"17","author":"MC Kiernan","year":"2021","unstructured":"Kiernan MC, Vucic S, Talbot K, McDermott CJ, Hardiman O, Shefner JM, et al. Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nat Rev Neurol. 2021;17(2):104\u201318. https:\/\/doi.org\/10.1038\/s41582-020-00434-z.","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"515_CR83","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.3390\/cells9081822","volume":"9","author":"B Baumert","year":"2020","unstructured":"Baumert B, Sobu\u015b A, Go\u0142\u0105b-Janowska M, Paczkowska E, \u0141uczkowska K, Rogi\u0144ska D, et al. Repeated application of autologous bone marrow-derived lineage-negative stem\/progenitor cells\u2014focus on immunological pathways in patients with ALS. Cells. 2020;9(8):1822. https:\/\/doi.org\/10.3390\/cells9081822.","journal-title":"Cells."},{"issue":"3","key":"515_CR84","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/mus.27339","volume":"64","author":"C Milligan","year":"2021","unstructured":"Milligan C, Atassi N, Babu S, Barohn RJ, Caress JB, Cudkowicz ME, et al. Tocilizumab is safe and tolerable and reduces C -reactive protein concentrations in the plasma and cerebrospinal fluid of ALS patients. Muscle Nerve. 2021;64(3):309\u201320. https:\/\/doi.org\/10.1002\/mus.27339.","journal-title":"Muscle Nerve"},{"issue":"11","key":"515_CR85","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/j.mayocp.2018.09.009","volume":"93","author":"J Rosenfeld","year":"2018","unstructured":"Rosenfeld J. Rethinking amyotrophic lateral sclerosis. Mayo Clin Proc. 2018;93(11):1543\u20135. https:\/\/doi.org\/10.1016\/j.mayocp.2018.09.009.","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"515_CR86","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1111\/j.1398-9995.2006.01058.x","volume":"61","author":"WJ Pichler","year":"2006","unstructured":"Pichler WJ. Adverse side-effects to biological agents. Allergy. 2006;61(8):912\u201320. https:\/\/doi.org\/10.1111\/j.1398-9995.2006.01058.x.","journal-title":"Allergy."},{"issue":"5","key":"515_CR87","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1586\/eci.09.31","volume":"5","author":"PJ Bugelski","year":"2009","unstructured":"Bugelski PJ, Achuthanandam R, Capocasale RJ, Treacy G, Bouman-Thio E. Monoclonal antibody-induced cytokine-release syndrome. Expert Rev Clin Immunol. 2009;5(5):499\u2013521. https:\/\/doi.org\/10.1586\/eci.09.31.","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"515_CR88","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2003715","volume":"383","author":"T Miller","year":"2020","unstructured":"Miller T, Cudkowicz M, Shaw PJ, Andersen PM, Atassi N, Bucelli RC, et al. Phase 1\u20132 trial of antisense oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2020;383(2):109\u201319. https:\/\/doi.org\/10.1056\/NEJMoa2003715.","journal-title":"N Engl J Med"},{"issue":"2","key":"515_CR89","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.bjae.2019.11.002","volume":"20","author":"EM Delhaas","year":"2020","unstructured":"Delhaas EM, Huygen FJPM. Complications associated with intrathecal drug delivery systems. BJA Educ. 2020;20(2):51\u20137. https:\/\/doi.org\/10.1016\/j.bjae.2019.11.002.","journal-title":"BJA Educ"},{"issue":"30","key":"515_CR90","doi-asserted-by":"publisher","first-page":"7697","DOI":"10.1200\/JCO.2005.02.4364","volume":"23","author":"SM O\u2019Brien","year":"2005","unstructured":"O\u2019Brien SM, Cunningham CC, Golenkov AK, Turkina AG, Novick SC, Rai KR. Phase I to II multicenter study of Oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J Clin Oncol. 2005;23(30):7697\u2013702. https:\/\/doi.org\/10.1200\/JCO.2005.02.4364.","journal-title":"J Clin Oncol"},{"issue":"2","key":"515_CR91","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/brainsci10020119","volume":"10","author":"BA Perez","year":"2020","unstructured":"Perez BA, Shutterly A, Chan YK, Byrne BJ, Corti M. Management of Neuroinflammatory Responses to AAV-mediated gene therapies for neurodegenerative diseases. Brain Sci. 2020;10(2):119. https:\/\/doi.org\/10.3390\/brainsci10020119.","journal-title":"Brain Sci"},{"issue":"8","key":"515_CR92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/01616412.2021.1893564","volume":"43","author":"G Je","year":"2021","unstructured":"Je G, Keyhanian K, Ghasemi M. Overview of stem cells therapy in amyotrophic lateral sclerosis. Neurol Res. 2021;43(8):1\u201317. https:\/\/doi.org\/10.1080\/01616412.2021.1893564.","journal-title":"Neurol Res"},{"key":"515_CR93","unstructured":"Research C for BE and. Update on Amyotrophic Lateral Sclerosis (ALS) Product Development. FDA. FDA; 2021. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/update-amyotrophic-lateral-sclerosis-als-product-development. Cited 2021 Apr 7."},{"issue":"3","key":"515_CR94","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000100","volume":"2","author":"RG Miller","year":"2015","unstructured":"Miller RG, Block G, Katz JS, Barohn RJ, Gopalakrishnan V, Cudkowicz M, et al. Randomized phase 2 trial of NP001-a novel immune regulator: safety and early efficacy in ALS. Neurol Neuroimmunol Neuroinflammation. 2015;2(3):e100. https:\/\/doi.org\/10.1212\/NXI.0000000000000100.","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"1","key":"515_CR95","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/s41467-019-14118-w","volume":"11","author":"D Schafflick","year":"2020","unstructured":"Schafflick D, Xu CA, Hartlehnert M, Cole M, Schulte-Mecklenbeck A, Lautwein T, et al. Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis. Nat Commun. 2020;11(1):247. https:\/\/doi.org\/10.1038\/s41467-019-14118-w.","journal-title":"Nat Commun"},{"issue":"2","key":"515_CR96","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/mus.26106","volume":"58","author":"R Raheja","year":"2018","unstructured":"Raheja R, Regev K, Healy BC, Mazzola MA, Beynon V, Von Glehn F, et al. Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis. Muscle Nerve. 2018;58(2):261\u20139. https:\/\/doi.org\/10.1002\/mus.26106.","journal-title":"Muscle Nerve"},{"key":"515_CR97","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3389\/fnmol.2018.00288","volume":"11","author":"M Liguori","year":"2018","unstructured":"Liguori M, Nuzziello N, Introna A, Consiglio A, Licciulli F, D\u2019Errico E, et al. Dysregulation of MicroRNAs and target genes networks in peripheral blood of patients with sporadic amyotrophic lateral sclerosis. Front Mol Neurosci. 2018;11:288. https:\/\/doi.org\/10.3389\/fnmol.2018.00288.","journal-title":"Front Mol Neurosci"},{"key":"515_CR98","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.neurobiolaging.2017.03.027","volume":"55","author":"R Waller","year":"2017","unstructured":"Waller R, Goodall EF, Milo M, Cooper-Knock J, Da Costa M, Hobson E, et al. Serum miRNAs miR-206, 143-3p and 374b-5p as potential biomarkers for amyotrophic lateral sclerosis (ALS). Neurobiol Aging. 2017;55:123\u201331. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2017.03.027.","journal-title":"Neurobiol Aging"},{"issue":"13","key":"515_CR99","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/S1474-4422(16)30246-0","volume":"15","author":"DC Henshall","year":"2016","unstructured":"Henshall DC, Hamer HM, Pasterkamp RJ, Goldstein DB, Kjems J, Prehn JHM, et al. MicroRNAs in epilepsy: pathophysiology and clinical utility. Lancet Neurol. 2016;15(13):1368\u201376. https:\/\/doi.org\/10.1016\/S1474-4422(16)30246-0.","journal-title":"Lancet Neurol"},{"issue":"12","key":"515_CR100","doi-asserted-by":"publisher","first-page":"8052","DOI":"10.1007\/s12035-019-1627-x","volume":"56","author":"A Dolinar","year":"2019","unstructured":"Dolinar A, Koritnik B, Glava\u010d D, Ravnik-Glava\u010d M. Circular RNAs as potential blood biomarkers in amyotrophic lateral sclerosis. Mol Neurobiol. 2019;56(12):8052\u201362. https:\/\/doi.org\/10.1007\/s12035-019-1627-x.","journal-title":"Mol Neurobiol"},{"issue":"1","key":"515_CR101","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12865-016-0144-1","volume":"17","author":"J Yang","year":"2016","unstructured":"Yang J, Diaz N, Adelsberger J, Zhou X, Stevens R, Rupert A, et al. The effects of storage temperature on PBMC gene expression. BMC Immunol. 2016;17(1):6. https:\/\/doi.org\/10.1186\/s12865-016-0144-1.","journal-title":"BMC Immunol"},{"issue":"4","key":"515_CR102","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.pneurobio.2011.04.012","volume":"95","author":"WT Hu","year":"2011","unstructured":"Hu WT, Trojanowski JQ, Shaw LM. Biomarkers in frontotemporal lobar degenerations\u2014Progress and challenges. Prog Neurobiol. 2011;95(4):636\u201348. https:\/\/doi.org\/10.1016\/j.pneurobio.2011.04.012.","journal-title":"Prog Neurobiol"},{"issue":"7329","key":"515_CR103","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/469156a","volume":"469","author":"G Poste","year":"2011","unstructured":"Poste G. Bring on the biomarkers. Nature. 2011;469(7329):156\u20137. https:\/\/doi.org\/10.1038\/469156a.","journal-title":"Nature."}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-022-00515-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-022-00515-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-022-00515-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T11:09:36Z","timestamp":1643022576000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-022-00515-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,24]]},"references-count":103,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["515"],"URL":"https:\/\/doi.org\/10.1186\/s13024-022-00515-1","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,24]]},"assertion":[{"value":"27 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11"}}